Adrenomedullin plasma levels predict left ventricular reverse remodeling after cardiac resynchronization therapy

PACE - Pacing and Clinical Electrophysiology

Volumn 33, Issue 7, 2010, Pages 865-872

  Morales, Maria Aurora ^a   Maltinti, Maristella ^a   Piacenti, Marcello ^a   Turchi, Stefano ^a   Giannessi, Daniela ^a   Ry, Silvia Del ^a  

^a FONDAZIONE TOSCANA GABRIELE MONASTERIO   (Italy)

Author keywords

adrenomedullin; cardiac resynchronization therapy; heart failure; natriuretic peptides

Indexed keywords

ADRENOMEDULLIN; BRAIN NATRIURETIC PEPTIDE;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CARDIAC RESYNCHRONIZATION THERAPY; CONTROLLED STUDY; DOPPLER ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; SINUS RHYTHM;

ADRENOMEDULLIN; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CARDIAC PACING, ARTIFICIAL; FEMALE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 77954362021     PISSN: 01478389     EISSN: 15408159     Source Type: Journal    
DOI: 10.1111/j.1540-8159.2010.02723.x     Document Type: Article

References (49)

1. McMurray JV, Pfeffer MA. Heart failure. Lancet 2005 365 : 1877 1888.
2. Ferrari R, Ceconi C, Curello S, Visioli O. The neuroendocrine and sympathetic nervous system in congestive heart failure. Eur Heart J 1998 19 : F45 F51.
3. Francis GS. Pathophysiology of chronic heart failure. Am J Med 2001 110 : 37S 46S.
4. McDonagh TA, Robb SD, Murdoch DR, Morton JJ, Ford I, Morrison CE, Tunstall-Pedoe H, et al. Biochemical detection of left-ventricular systolic dysfunction. Lancet 1998 351 : 9 13.
5. Stanek B, Frey B, Hülsmann M, Berger R, Sturm B, Strametz-Juranek J, Bergler-Klein J, et al. Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction. J Am Coll Cardiol 2001 38 : 436 442.
6. Angermann CE, Ertl G. Natriuretic peptides - new diagnostic markers in heart disease. Herz 2004 29 : 609 617.
7. Tsutamoto T, Wada A, Maeda K, Hisanaga T, Maeda Y, Fukai D, Ohnishi M, et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: Prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation 1997 96 : 509 516.
8. Butter C, Auricchio A, Stellbrink C, Fleck E, Ding J, Yu Y, Huvelle E, et al. Effect of resynchronization therapy stimulation site on the systolic function of heart failure patients. Circulation 2001 104 : 3026 3029.
9. Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, Tavazzi L. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005 352 : 1539 1549. (Pubitemid 40517094)
10. Saxon LA, Ellenbogen KA. Resynchronization therapy for the treatment of heart failure. Circulation 2003 108 : 1044 1048.
11. St John Sutton MG, Plappert T, Abraham WT, Smith AL, DeLurgio DB, Leon AR, Loh E, et al. Effect of cardiac resynchronization therapy on left ventricular size and function in chronic heart failure. Circulation 2003 107 : 1985 1990.
12. Rossi A, Rossi G, Startari U, Panchetti L, Piacenti M, Morales MA. The current role of cardiac resynchronization therapy in reducing mortality and hospitalization in heart failure patients. A meta-analysis from clinical trials. Heart Vessels 2008 23 : 217 223.
13. Vardas PE, Auricchio A, Blanc JJ, Daubert JC, Drexler H, Ector H, Gasparini M, et al. Guidelines for cardiac pacing and cardiac resynchronization therapy. Eur Heart J 2007 18 : 2256 2295.
14. Braun MU, Rauwolf T, Zerm T, Schulze M, Schnabel A, Strasser RH. Long term biventricular resynchronisation therapy in advanced heart failure: Effect on neurohormones. Heart 2005 91 : 601 605.
15. Kubanek M, Malek I, Bytesnik J, Fridl P, Riedlbauchova L, Karasova L, Lanska V, et al. Decrease in plasma B-type natriuretic peptide early after initiation of cardiac resynchronization therapy predicts clinical improvement at 12 months. Eur J Heart Failure 2006 8 : 832 840.
16. Molhoek SG, Bax JJ, Van Erven L, Bootsma M, Steendijk P, Lenties E, Boersma E, et al. Atrial and brain natriuretic peptides as markers of response to resynchronisation theraphy. Heart 2004 90 : 97 98.
17. Ricciardi C, Pieragnoli P, Colella A, Giaccardi M, Padeletti L, Abbate R, Gensini GF, et al. Role of natriuretic peptides in heart failure patients with special reference on cardiac resyncronization therapy. Minerva Cardioangiol 2006 54 : 743 752.
18. Lellouche N, De Diego C, Cesario DA, Vaseghi M, Natterson Horowitz B, Mahajan A, Wiener I, et al. Usefulness of preimplantation B-type natriuretic peptide level for predicting response to cardiac resynchronization therapy. Am J Cardiol 2007 99 : 242 246.
19. Pitzalis MV, Iacoviello M, Di Serio F, Romito R, Guida P, De Tommasi E, Luzzi G, et al. Prognostic value of brain natriuretic peptide management of patients receiving cardiac resynchronization therapy. Eur J Heart Fail 2006 8 : 509 514.
20. Fruhwald FM, Fahrleitner-Pammer A, Berger R, Leyva F, Freemantle N, Erdmann E, Gras D, et al. Early and sustained effects of cardiac resynchronization therapy on N-terminal pro-B-type natriuretic peptide in patients with moderate to severe heart failure and cardiac dyssynchrony. Eur Heart J 2007 28 : 1592 1597.
21. Maeda K, Tsutamoto T, Wada A, Mabuchi N, Hayashi M, Tsutsui T, Ohnishi M, et al. High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure. J Am Coll Cardiol 2000 36 : 1587 1593.
22. Cappola TP, Harsch MR, Jessup M, Abraham WT, Young JB, Petersen-Stejskal S, Plappert T, et al. Predictors of remodeling in the CRT era: Influence of mitral regurgitation, BNP, and gender. J Card Fail 2006 122 : 182 188.
23. Wang RX, Guo T, Li XR. BNP/NT-ProBNP and cardiac pacing: A review. Pace 2009 32 : 794 799.
24. Pousset F, Masson F, Chaviroskaia O, Isnard R, Carayon A, Golmard JL, Lechat P, et al. Plasma adrenomedullin, a new independent predictor of prognosis in patients with chronic heart failure. Eur Heart J 2000 21 : 1009 1014.
25. Ishimitsu T, Ono H, Minami J, Matsuoka H. Pathophysiologic and therapeutic implications of adrenomedullin in cardiovascular disorders. Pharmacol Therapet 2006 111 : 909 927.
26. Parkes DG. Cardiovascular actions of adrenomedullin in conscious sheep. Am J Physiol 1995 268 : H2574 H2578.
27. Tian Q, Zhao D, Tan DY, Zhao YT, Li QH, Qiu JX, Song LW, et al. Vasodilator effect of human adrenomedullin (13-52) on hypertensive rats. Can J Physiol Pharmacol 1995 73 : 1065 1069.
28. Nishikimi T, Saito Y, Kitamura K, Ishimitsu T, Eto T, Kangawa K, Matsuo H, et al. Increased plasma levels of adrenomedullinin patients with heart failure. J Am Coll Cardiol 1995 26 : 1424 1431.
29. Jougasaki M, Rodeheffer RJ, Redfield MM, Yamamoto K, Wei CM, McKinley LJ, Burnett JC Jr., et al. Cardiac secretion of adrenomedullin in human heart failure. J Clin Invest 1996 97 : 2370 2376.
30. World Medical Organization. Declaration of Helsinki. Br Med J 1996 313 : 1448 1449.
31. Morales M-A, Del Ry S, Startari U, Maltinti M, Prontera C, Emdin M, Giannessi D. Plasma adrenomedullin relation with Doppler derived dP/dt in patients with congestive heart failure. Clin Cardiol 2006 29 : 126 130.
32. Clerico A, Iervasi G, Del Chicca MG, Emdin M, Maffei S, Nannipieri M, Sabatino L, et al. Circulating levels of cardiac natriuretic peptides (ANP and BNP) measured by highly sensitive and specific immunoradiometric assays in normal subjects and in patients with different degrees of heart failure. J Endocrinol Invest 1998 21 : 170 179.
33. Del Ry S, Clerico A, Giannessi D, Andreassi MG, Caprioli R, Iascone MR, Biagini A, et al. Measurement of BNP in plasma samples in cardiac tissue extracts by means of an IRMA method. Scand J Clin Lab Invest 2000 60 : 81 90.
34. Schiller NB, Acquatella H, Ports TA, Drew D, Goerke J, Ringertz H, Silverman NH, et al. Left ventricular volume from paired biplane two-dimensional echocardiography. Circulation 1979 60 : 547 555.
35. Pilo A, Zucchelli GC, Malvano R, Masini S. Main features of computer algorithms for RIA data reduction. Comparison of same different approaches for the interpolation of dose-response curve. J Nucl Med All Sci 1982 26 : 235 248.
36. Abraham WT, Fisher WG, Smith AL, Delurgio DB, Leon AR, Loh E, Kocovic DZ, et al. Cardiac resynchronization in chronic heart failure. N Engl J Med 2002 346 : 1845 1853.
37. Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, Carson T, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004 350 : 2140 2150.
38. McAlister FA, Ezekowitz JA, Wiebe N, Rowe B, Spooner C, Crumley E, Hartling L, et al. Systematic review: Cardiac resynchronization in patients with symptomatic heart failure. Ann Int Med 2004 141 : 381 390.
39. Boriani G, Biffi M, Martignani C, Fallani F, Greco C, Grigioni F, Corazza I, et al. Cardiac resynchronization by pacing: An electrical treatment of heart failure. Int J Cardiol 2004 94 : 151 161.
40. Cleland JG, Freemantle N, Ghio S, Fruhwald F, Shankar A, Marijanowski M, Verboven Y, et al. Predicting the long-termeffects of cardiac resynchronisation therapy on mortality from baseline variables and the early response: A report from CARE-HF (Cardiac Resynchronisation in Heart Failure). J Am Coll Cardiol 2008 52 : 438 445.
41. Sitges M, Vidal B, Delgado V, Mont L, Garcia-Alvarez A, Tolosana JM, Castel A, et al. Long-term effect of cardiac resynchronization therapy on functional mitral valve regurgitation. Am J Cardiol 2009 104 : 383 388.
42. Marsan NA, Bleeker GB, Ypenburg C, Van Bommel RJ, Ghio S, Van de Veire NR, Delgado V, et al. Real-time three-dimensional echocardiography as a novel approach to assess left ventricular and left atrium reverse remodeling and to predict response to cardiac resynchronization therapy. Heart Rhythm 2008 5 : 1257 1264.
43. Saxon LA, De Marco T, Schafer J, Chatterjee K, Kumar UN, Foster E VIGOR Congestive Heart Failure Investigators. Effects of long-term biventricular stimulation for resynchronization on echocardiographic measures of remodelling. Circulation 2002 105 : 1304 1310.
44. Sinha AM, Filzmaier K, Breithardt OA, Kunz D, Graf J, Markus KU, Hanrath P, et al. Usefulness of brain natriuretic peptide release as a surrogate marker of the efficiency of long-term cardiac resynchronization therapy in patients with heart failure. Am J Cardiol 2003 91 : 755 758.
45. Cleland JGF, Tavazzi L, Daubert JC, Tageldien A, Freemantle N. CRT: Are modern myths preventing appropriate use? J Am Coll Cardiol 2009 53 : 608 611.
46. Richards AM, Doughty R, Nicholls MG, MacMahon S, Sharpe N, Murphy J, Espiner EA, et al. Plasma N-Terminal Pro-Brain natriuretic peptide and adrenomedullin. J Am College Cardiol 2001 37 : 1781 1787.
47. Miyao Y, Nishikimi T, Goto Y, Miyazaki S, Daikoku S, Morii I, Matsumoto T, et al. Increased plasma adrenomedullin levels in patients with acute myocardial infarction in proportion to the clinical severity. Heart 1998 79 : 39 44.
48. Katayama T, Nakashima H, Honda Y, Suzuki S, Yano K. Relationship between adrenomedullin and left-ventricular systolic function and mortality in acute myocardial infarction. Angiology 2005 56 : 34 52.
49. Bleeker GB, Bax JJ, Wing-Hong Fung J, van der Wall EE, Zhang Q, Schalij MJ, Yat-Sun Chan J, et al. Clinical versus echocardiographic parameters to assess response to cardiac resynchronization therapy. Am J Cardiol 2006 97 : 260 263.